Shanghai Baize Medical Technology

Shanghai Baize Medical Technology is a clinical-stage biotechnology company focused on the research and development of next-generation cell therapies for oncology. The company specializes in Chimeric Antigen Receptor T-cell (CAR-T) technologies designed to treat solid tumors, which remain a significant challenge in immunotherapy. Baize Medical's pipeline includes several candidates targeting Glypican-3 (GPC3) and HER2, with a primary focus on liver cancer and other refractory solid malignancies. By optimizing CAR-T cell persistence and infiltration, the company seeks to provide curative options for patients with advanced cancers.